Geode Capital Management LLC Grows Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Geode Capital Management LLC boosted its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 1.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 920,363 shares of the company's stock after acquiring an additional 14,015 shares during the period. Geode Capital Management LLC owned about 1.91% of Amphastar Pharmaceuticals worth $44,674,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of AMPH. GAMMA Investing LLC lifted its holdings in shares of Amphastar Pharmaceuticals by 70.0% in the 3rd quarter. GAMMA Investing LLC now owns 663 shares of the company's stock valued at $32,000 after purchasing an additional 273 shares during the last quarter. Innealta Capital LLC acquired a new position in Amphastar Pharmaceuticals during the second quarter worth approximately $55,000. Point72 Asia Singapore Pte. Ltd. lifted its stake in Amphastar Pharmaceuticals by 53.4% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company's stock valued at $56,000 after buying an additional 398 shares during the last quarter. Asset Management One Co. Ltd. acquired a new stake in shares of Amphastar Pharmaceuticals in the third quarter valued at approximately $78,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Amphastar Pharmaceuticals by 20.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company's stock valued at $85,000 after acquiring an additional 301 shares during the period. Institutional investors and hedge funds own 65.09% of the company's stock.

Amphastar Pharmaceuticals Stock Performance

Shares of NASDAQ AMPH traded down $0.85 during mid-day trading on Tuesday, hitting $38.27. 305,165 shares of the company were exchanged, compared to its average volume of 415,345. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The firm has a market cap of $1.84 billion, a price-to-earnings ratio of 12.76, a price-to-earnings-growth ratio of 0.87 and a beta of 0.78. The stock has a 50 day simple moving average of $46.26 and a 200-day simple moving average of $44.56. Amphastar Pharmaceuticals, Inc. has a 1-year low of $36.56 and a 1-year high of $65.92.

Insider Transactions at Amphastar Pharmaceuticals

In related news, EVP Rong Zhou sold 7,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $44.42, for a total value of $310,940.00. Following the sale, the executive vice president now directly owns 118,469 shares in the company, valued at $5,262,392.98. The trade was a 5.58 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Yakob Liawatidewi sold 5,214 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total value of $271,388.70. Following the completion of the transaction, the executive vice president now owns 74,938 shares of the company's stock, valued at $3,900,522.90. The trade was a 6.51 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 41,533 shares of company stock worth $1,987,482. Company insiders own 27.10% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. StockNews.com cut shares of Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, November 1st. Wells Fargo & Company started coverage on shares of Amphastar Pharmaceuticals in a report on Friday, November 22nd. They issued an "equal weight" rating and a $55.00 target price for the company. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat.com, Amphastar Pharmaceuticals currently has a consensus rating of "Hold" and a consensus target price of $60.33.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.